Now showing items 1-3 of 3
One size does not fit all: The merit of absorbed doses to the blood in 131i therapy for differentiated thyroid carcinoma
The amount of 131I necessary for successful ablation in patients with differentiated thyroid cancer (DTC) is still subject to debate. This study investigates the relationship of the absorbed dose of radiation to the blood ...
Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with 131I: Comparison of the efficacy of pantoprazole, metoclopra-mide, and ondansetron – a randomized clinical trial [Behandlung gastrointestinaler beschwerden unter 131I-therapie bei patienten mit differenzier-tem schilddrüsenkarzinom: Vergleich der wirksamkeit von pantoprazol, meto-clopramid und ondansetron – eine randomisierte klinische prüfung]
Objective: To compare safety and efficacy of pantoprazol, metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients. ...
Evaluation of prognostic factors associated with differentiated thyroid carcinoma with pulmonary metastasis
Background: Because one of the major sites for metastasis of thyroid cancers is the lung, studying the pattern of pulmonary metastasis may provide useful information for the effective treatment of these patients. In this ...